Thermo Fisher Scientific Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Thermo Fisher Scientific Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 5.7 times. Higher than 89% of Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $41 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 87% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$131Over the last 3 years, every $100 of reported profit came with $131 of operating cash.
Lower than 64% of Healthcare companies in United States.
Self-Funding Ratio
5.7×Over the last 3 years its own operating cash covered its investment spending (capex) 5.7 times.
Higher than 89% of Healthcare companies in United States.
Cash Locked Ratio
$28For every $100 of sales, $28 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $26 tied up three years earlier.
More money tied up than 60% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales barely changed
Sales changed by -1% in 3 years, too little to measure extra profit per extra sales.
Asset Productivity Ratio
-1% / +14%In 3 years sales changed by -1% while total assets changed by +14%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
2.2×Debt due within a year is covered 2.2 times by its yearly operating cash.
Higher than 74% of Healthcare companies in United States.
Cash Cushion Ratio
−12%Debt, after subtracting cash, equals 12% of its market value (net debt).
Lower than 79% of Healthcare companies in United States.
Tangible Assets Ratio
41%Of every $100 the company owns, $41 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 87% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 80% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Thermo Fisher Scientific Inc. owes $0.53 for every $1 it owns. Net profit rose 6% in the year to Dec 2025, and shrank 1% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
35.7Investors pay $35.7 for every $1 of Thermo Fisher Scientific Inc.'s yearly profit, higher than 65% of Healthcare companies in United States.
P/B ratio
4.75The share price is 4.75 times Thermo Fisher Scientific Inc.'s book value per share, higher than 70% of Healthcare companies in United States.
Market cap
$250.1 BThe total market value of all of Thermo Fisher Scientific Inc.'s shares at today's price (share price × number of shares), larger than almost all Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$52.7 BWhat Thermo Fisher Scientific Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$142.48Net worth divided by the number of shares. The share price of $676.54 is 4.7 times this, which is the P/B above.
Return on equity (ROE)
13.4%Thermo Fisher Scientific Inc. earned 13.4% on its shareholders' money over the last year, higher than 86% of Healthcare companies in United States.
Owes vs Owns
0.53×Thermo Fisher Scientific Inc. owes $0.53 for every $1 it owns (moderate), higher than 59% of Healthcare companies in United States.
Dividend yield
0.27%Thermo Fisher Scientific Inc. pays 0.27% of its share price as dividends a year, lower than 90% of dividend-paying Healthcare companies in United States.
Revenue growth
+4%Revenue rose 4% in the year to Dec 2025, and shrank 0% a year on average over 3 years.
Profit growth
+6%Net profit rose 6% in the year to Dec 2025, and shrank 1% a year on average over 3 years.
Profit margin
15.0%Thermo Fisher Scientific Inc. keeps $15 of every $100 of revenue as net profit.
Cash quality
1.2×Cash from Thermo Fisher Scientific Inc.'s business was 1.2× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
5.7×Thermo Fisher Scientific Inc.'s operating profit covered its interest costs 5.7 times in the year to Dec 2025.
Cash vs debt
Net debtThermo Fisher Scientific Inc. had $29.3 B more debt than cash (net debt) at Dec 2025.
Questions
What is Thermo Fisher Scientific Inc.'s P/E ratio?
Investors pay $35.7 for every $1 of Thermo Fisher Scientific Inc.'s yearly profit, higher than 65% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Thermo Fisher Scientific Inc.: $250.1 B ÷ $52.7 B (30 Jun 2026) = 4.7.
What is Thermo Fisher Scientific Inc.'s return on equity?
Thermo Fisher Scientific Inc. earned 13.4% on its shareholders' money over the last year, higher than 86% of Healthcare companies in United States.
How much does Thermo Fisher Scientific Inc. owe compared with what it owns?
Thermo Fisher Scientific Inc. owes $0.53 for every $1 it owns (moderate), higher than 59% of Healthcare companies in United States.
Does Thermo Fisher Scientific Inc. pay a dividend?
Yes. Thermo Fisher Scientific Inc. pays 0.27% of its share price as dividends a year, lower than 90% of dividend-paying Healthcare companies in United States.
Is Thermo Fisher Scientific Inc.'s revenue growing?
Revenue rose 4% in the year to Dec 2025, and shrank 0% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.